XML 78 R56.htm IDEA: XBRL DOCUMENT
v3.24.0.1

Significant Accounting Policies - Disaggregation of Revenue (Details) - USD ($) $ in Millions | 12 Months Ended
--- | ---
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021
Disaggregation of Revenue [Line Items] |  |  |
Revenues | $ 356,623 | $ 321,629 | $ 290,912
Net investment income (loss) | 1,153 | 838 | 1,199
Total revenues | 357,776 | 322,467 | 292,111
Pharmacy |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Revenues | 223,452 | 205,119 | 184,619
Front Store |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Revenues | 22,458 | 22,780 | 21,315
Premiums |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Revenues | 99,192 | 85,330 | 76,132
Other |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Revenues | 11,521 | 8,400 | 8,846
Operating Segments | Health Care Benefits |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Revenues | 104,800 | 90,798 | 81,457
Net investment income (loss) | 765 | 476 | 586
Total revenues | 105,646 | 91,350 | 82,119
Operating Segments | Health Care Benefits | Pharmacy |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Revenues | 0 | 0 | 0
Operating Segments | Health Care Benefits | Front Store |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Revenues | 0 | 0 | 0
Operating Segments | Health Care Benefits | Premiums |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Revenues | 99,144 | 85,274 | 76,064
Operating Segments | Health Care Benefits | Other |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Revenues | 5,737 | 5,600 | 5,469
Operating Segments | Health Services |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Revenues | 174,018 | 157,968 | 143,912
Net investment income (loss) | (1) | 0 | 0
Total revenues | 186,843 | 169,576 | 153,892
Operating Segments | Health Services | Pharmacy network |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 112,718 | 102,968 | 96,834
Operating Segments | Health Services | Mail choice |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 67,992 | 63,825 | 53,812
Operating Segments | Health Services | Other |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 6,134 | 2,783 | 3,246
Operating Segments | Health Services | Pharmacy |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Revenues | 180,710 | 166,793 | 150,646
Operating Segments | Health Services | Front Store |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Revenues | 0 | 0 | 0
Operating Segments | Health Services | Premiums |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Revenues | 0 | 0 | 0
Operating Segments | Health Services | Other |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Revenues | 6,134 | 2,783 | 3,246
Operating Segments | Pharmacy & Consumer Wellness |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Revenues | 77,748 | 72,739 | 65,418
Net investment income (loss) | (5) | (44) | 17
Total revenues | 116,763 | 108,596 | 101,620
Operating Segments | Pharmacy & Consumer Wellness | Pharmacy |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Revenues | 92,111 | 83,480 | 77,886
Operating Segments | Pharmacy & Consumer Wellness | Front Store |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Revenues | 22,458 | 22,780 | 21,315
Operating Segments | Pharmacy & Consumer Wellness | Premiums |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Revenues | 0 | 0 | 0
Operating Segments | Pharmacy & Consumer Wellness | Other |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Revenues | 2,199 | 2,380 | 2,402
Corporate/ Other | Corporate/ Other |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Revenues | 57 | 124 | 125
Net investment income (loss) | 394 | 406 | 596
Total revenues | 451 | 530 | 721
Corporate/ Other | Corporate/ Other | Pharmacy |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Revenues | 0 | 0 | 0
Corporate/ Other | Corporate/ Other | Front Store |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Revenues | 0 | 0 | 0
Corporate/ Other | Corporate/ Other | Premiums |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Revenues | 48 | 56 | 68
Corporate/ Other | Corporate/ Other | Other |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Revenues | 9 | 68 | 57
Intersegment Eliminations |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net investment income (loss) | 0 | 0 | 0
Total revenues | (51,927) | (47,585) | (46,241)
Intersegment Eliminations | Pharmacy |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Revenues | (49,369) | (45,154) | (43,913)
Intersegment Eliminations | Front Store |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Revenues | 0 | 0 | 0
Intersegment Eliminations | Premiums |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Revenues | 0 | 0 | 0
Intersegment Eliminations | Other |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Revenues | $ (2,558) | $ (2,431) | $ (2,328)

X
- Definition Premiums Earned, Net And Revenue From Contract With Customer, Excluding Assessed Tax + References No definition available. + Details
Name: | cvs_PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | cvs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91 Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91 Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91 Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91 Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91 Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91 Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91 + Details
Name: | us-gaap_DisaggregationOfRevenueLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, after investment expense, of income earned from investments in securities and real estate. Includes, but is not limited to, real estate investment, policy loans, dividends, and interest. Excludes realized gain (loss) on investments. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(2)(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 5 -SubTopic 220 -Topic 946 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-5 + Details
Name: | us-gaap_NetInvestmentIncome
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42 Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40 Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22 Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41 Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1 + Details
Name: | us-gaap_Revenues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_ProductOrServiceAxis=cvs_PharmacyRevenueMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=cvs_FrontStoreRevenueMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=cvs_PremiumsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=cvs_HealthCareBenefitsSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=cvs_HealthServicesSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContractWithCustomerSalesChannelAxis=us-gaap_SalesChannelThroughIntermediaryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContractWithCustomerSalesChannelAxis=us-gaap_SalesChannelDirectlyToConsumerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContractWithCustomerSalesChannelAxis=cvs_SalesChannelOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=cvs_PharmacyAndConsumerHealthSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ConsolidationItemsAxis=cvs_CorporateAndReconcilingItemsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=cvs_CorporateAndOtherSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |